Rapamycin for Longevity: What the Research Shows
Rapamycin has the strongest animal lifespan evidence of any compound and no human longevity trial. What that gap actually means, and what the off-label practice rests on.
The Short Answer
Rapamycin, known as sirolimus in clinical use, is a prescription macrolide that inhibits mTORC1 and has extended median and maximum lifespan in mice reproducibly across multiple independent sites, doses, both sexes, and even when started in late life. No compound in the field has a stronger animal record. In humans it is an approved immunosuppressant and anti-proliferative agent with a fully characterised profile at transplant and oncology doses, and there is no completed longevity trial at any dose. The off-label practice of weekly low-dose use is an extrapolation from animal data supported by early human tolerability work, not an evidence-based protocol, and it is a prescription decision rather than a supplement one.
Mechanism: The mTOR Brake
Rapamycin binds the intracellular protein FKBP12, and the resulting complex inhibits mTORC1, the nutrient- and growth-sensing kinase complex that decides whether a cell builds or maintains.
With mTORC1 inhibited, protein synthesis and cell growth slow, and autophagy is released from suppression. Autophagic clearance of damaged proteins and mitochondria increases, which is the mechanism through which the lifespan effect appears to operate: genetically disabling autophagy abolishes the lifespan extension.
The second complex, mTORC2, is not directly inhibited by acute rapamycin exposure, but chronic exposure does affect it, and mTORC2 inhibition is thought to account for the glucose intolerance and lipid changes seen with continuous dosing. This asymmetry is the entire rationale for intermittent dosing: mTORC1 inhibition is the objective, and giving the drug weekly rather than daily is an attempt to hit the target while letting mTORC2 signalling recover between doses.
The Animal Evidence
This is where rapamycin is unmatched.
In the multi-site programme that tests candidate compounds in genetically heterogeneous mice specifically to filter out single-laboratory artefacts, rapamycin extended median and maximum lifespan reproducibly, at several doses, in both sexes, with larger effects at higher doses. Crucially, it worked when started at twenty months of age, which in mouse terms is late life. Very few interventions restore anything in an already-old animal.
Beyond lifespan, animal work reports improved cardiac function in old mice, delayed cognitive decline, improved immune function in aged animals, reduced tumour incidence in some models, periodontal improvement in dogs, and improved ovarian reserve in female mice. Lifespan extension has also been shown in yeast, nematodes and flies, making mTOR inhibition one of the few interventions conserved across that evolutionary distance.
Work in marmosets and the ongoing veterinary trial in companion dogs are the closest existing tests in longer-lived mammals.
The Human Evidence
Two distinct bodies of evidence exist, and conflating them is the standard error.
Clinical use. Sirolimus and everolimus are approved for transplant immunosuppression, for certain cancers, and for specific rare conditions. At those doses and schedules the profile is well characterised: immunosuppression with infection consequences, mouth ulcers, impaired wound healing, glucose intolerance, dyslipidaemia, proteinuria, and interstitial lung effects in a minority. This tells us what continuous therapeutic dosing does. It does not describe weekly low-dose use.
Aging-adjacent trials. A trial of a rapalog in older adults reported improved antibody response to influenza vaccination and fewer reported infections, which is notable because it suggests intermittent mTOR inhibition can improve rather than suppress an aged immune system. A decentralised trial of intermittent low-dose rapamycin in healthy adults over roughly a year reported tolerability with mostly minor adverse events and some changes in self-reported and body composition measures, without demonstrating an effect on aging. Trials in specific age-related conditions are ongoing.
What does not exist. Any trial with a longevity or healthspan primary endpoint, any multi-year safety data at longevity doses, and any established dose or schedule. The people using it are running an uncontrolled personal experiment, and the honest ones say so.
The Off-Label Practice, Described Neutrally
The pattern reported in the longevity community is weekly dosing, commonly in the region of five to seven milligrams once per week, sometimes with periodic breaks, prescribed by a physician willing to do so and monitored with periodic bloods.
The reasoning behind that schedule: mTORC1 inhibition from a single dose persists for days, weekly dosing keeps average exposure low, and animal work with intermittent regimens has produced benefit while reducing the metabolic effects of continuous exposure. That reasoning is coherent. It is also reasoning, and the dose was not established by human dose-finding for this purpose.
Monitoring in that practice typically includes a full blood count, metabolic panel, lipids, HbA1c and periodic assessment for mouth ulcers and infections. Timing around vaccination, surgery and wound healing requires planning, since impaired healing and blunted or altered immune response are real considerations.
None of this constitutes a recommendation. It is a description of what is happening, offered because pretending it is not happening serves nobody.
The Considerations That Matter
- Immune function. The direction of effect at low intermittent doses may be favourable in an aged immune system, and it is dose-dependent and not fully mapped. Infection risk, live vaccine timing and wound healing all sit here.
- Glucose and lipids. Continuous dosing impairs glucose handling and raises lipids. Intermittent dosing is intended to avoid this, and it deserves monitoring rather than assumption.
- Mouth ulcers. The most common dose-limiting effect in practice, and often the signal that a dose is too high for that individual.
- Surgery and healing. Impaired wound healing is well documented at clinical doses and argues for a break before any planned procedure.
- Fertility and pregnancy. Contraindicated in pregnancy, and effects on male and female fertility are not benign.
- Interactions. Rapamycin is metabolised by CYP3A4, so grapefruit, many prescription drugs, and several supplements including berberine and quercetin can raise its concentration substantially.
- It is a prescription drug. Sourcing it outside a prescribing relationship removes the monitoring that makes the practice defensible at all.
An Honest Position
Rapamycin is simultaneously the most convincing longevity compound in animals and one of the least appropriate for casual use. Both statements are true and neither cancels the other.
What can be said with confidence: mTOR inhibition is a genuine longevity mechanism, conserved across species, and rapamycin is the most reliable pharmacological way to achieve it. What cannot be said: that a weekly dose in a healthy human extends healthspan, that any particular dose is correct, or that multi-year use at those doses is safe. Those are open questions with trials running.
For anyone weighing it, three things follow. It belongs in a prescribing relationship with monitoring, not in a supplement stack. The non-pharmacological routes to the same mechanism, fasting windows, energy balance, exercise and protein distribution, are available now with no downside and are what the evidence supports for a general audience. And the review trigger is external: the trials underway will change this picture, and the sensible position is to watch them rather than to front-run them.
The AEONNN Perspective
AEONNN is a wellness platform, and prescription compounds sit outside the boundary of supplement intelligence by design. Rapamycin is not something Stack Builder recommends, at any dose, and the Safety layer handles prescription-only status as a categorical exclusion rather than a weighting.
Its place in the Journal is educational, because a member reading about mTOR, autophagy and the hallmarks of aging will encounter rapamycin as the strongest animal result in the field and deserves an accurate account of both the strength of that result and the size of the gap to human evidence.
What AEONNN can act on is the same mechanism through the routes available to a wellness platform: feeding windows, energy balance, protein distribution and training, all of which sit in Cellular Energy and Repair and Metabolic and Cardiovascular Health. The Innovation layer tracks the human trials, because their results will change what this article says.
Pillar Matrix mapping
Cellular Energy and Repair, Inflammation and Immune Defense, Longevity and Biological Age
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Mechanistic Layer (KEGG, Reactome, UniProt)
- Safety Layer (DrugBank, FAERS)
- Regulatory Layer (EFSA, FDA, EMA)
- Innovation Layer (bioRxiv preprints, patent filings)
Frequently Asked
Does rapamycin extend lifespan in humans?
Unknown. No trial with a longevity or healthspan primary endpoint has been completed. It extends median and maximum lifespan in mice reproducibly across multiple sites and doses, including when started in late life.
What dose do people use off-label?
The reported pattern is roughly five to seven milligrams once weekly, sometimes with breaks, under a prescribing physician with periodic bloods. That dose comes from scaling animal work and community practice rather than human dose-finding for this purpose.
Why weekly rather than daily?
Acute exposure inhibits mTORC1, the target, while chronic exposure also affects mTORC2, which is associated with glucose intolerance and lipid changes. Weekly dosing is an attempt to hit the target while allowing mTORC2 signalling to recover.
Does rapamycin suppress the immune system?
At clinical transplant doses, yes, by design. At low intermittent doses the picture is different: a rapalog trial in older adults reported improved influenza vaccination response and fewer infections. The effect is dose-dependent and not fully mapped.
What are the common side effects at low doses?
Mouth ulcers are the most frequently reported and often the dose-limiting effect. Glucose and lipid changes, impaired wound healing and infection considerations are the ones that require monitoring.
Does anything interact with rapamycin?
Yes, substantially. It is metabolised by CYP3A4, so grapefruit, many prescription drugs and several supplements including berberine and quercetin can raise its concentration.
Is there a supplement that does what rapamycin does?
No supplement reproduces mTORC1 inhibition at that potency. Fasting windows, energy balance, exercise and protein distribution act on the same pathway and are what the evidence supports for a general audience.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.